S&P 500   3,772.96 (-0.27%)
DOW   30,150.43 (-0.41%)
QQQ   283.52 (+0.55%)
AAPL   147.05 (+0.44%)
MSFT   249.89 (+0.28%)
META   138.52 (-0.33%)
GOOGL   102.30 (+0.86%)
AMZN   120.76 (-0.16%)
TSLA   243.36 (+1.06%)
NVDA   136.06 (+3.01%)
NIO   15.99 (-0.31%)
BABA   84.95 (+0.66%)
AMD   69.97 (+2.99%)
T   15.75 (-1.13%)
MU   54.85 (+0.22%)
CGC   3.12 (+1.63%)
F   12.58 (+0.56%)
GE   67.35 (-0.13%)
DIS   101.18 (+0.38%)
AMC   7.54 (+2.86%)
PYPL   94.39 (+0.60%)
PFE   43.72 (-0.91%)
NFLX   238.21 (+0.63%)
S&P 500   3,772.96 (-0.27%)
DOW   30,150.43 (-0.41%)
QQQ   283.52 (+0.55%)
AAPL   147.05 (+0.44%)
MSFT   249.89 (+0.28%)
META   138.52 (-0.33%)
GOOGL   102.30 (+0.86%)
AMZN   120.76 (-0.16%)
TSLA   243.36 (+1.06%)
NVDA   136.06 (+3.01%)
NIO   15.99 (-0.31%)
BABA   84.95 (+0.66%)
AMD   69.97 (+2.99%)
T   15.75 (-1.13%)
MU   54.85 (+0.22%)
CGC   3.12 (+1.63%)
F   12.58 (+0.56%)
GE   67.35 (-0.13%)
DIS   101.18 (+0.38%)
AMC   7.54 (+2.86%)
PYPL   94.39 (+0.60%)
PFE   43.72 (-0.91%)
NFLX   238.21 (+0.63%)
S&P 500   3,772.96 (-0.27%)
DOW   30,150.43 (-0.41%)
QQQ   283.52 (+0.55%)
AAPL   147.05 (+0.44%)
MSFT   249.89 (+0.28%)
META   138.52 (-0.33%)
GOOGL   102.30 (+0.86%)
AMZN   120.76 (-0.16%)
TSLA   243.36 (+1.06%)
NVDA   136.06 (+3.01%)
NIO   15.99 (-0.31%)
BABA   84.95 (+0.66%)
AMD   69.97 (+2.99%)
T   15.75 (-1.13%)
MU   54.85 (+0.22%)
CGC   3.12 (+1.63%)
F   12.58 (+0.56%)
GE   67.35 (-0.13%)
DIS   101.18 (+0.38%)
AMC   7.54 (+2.86%)
PYPL   94.39 (+0.60%)
PFE   43.72 (-0.91%)
NFLX   238.21 (+0.63%)
S&P 500   3,772.96 (-0.27%)
DOW   30,150.43 (-0.41%)
QQQ   283.52 (+0.55%)
AAPL   147.05 (+0.44%)
MSFT   249.89 (+0.28%)
META   138.52 (-0.33%)
GOOGL   102.30 (+0.86%)
AMZN   120.76 (-0.16%)
TSLA   243.36 (+1.06%)
NVDA   136.06 (+3.01%)
NIO   15.99 (-0.31%)
BABA   84.95 (+0.66%)
AMD   69.97 (+2.99%)
T   15.75 (-1.13%)
MU   54.85 (+0.22%)
CGC   3.12 (+1.63%)
F   12.58 (+0.56%)
GE   67.35 (-0.13%)
DIS   101.18 (+0.38%)
AMC   7.54 (+2.86%)
PYPL   94.39 (+0.60%)
PFE   43.72 (-0.91%)
NFLX   238.21 (+0.63%)
NASDAQ:LGND

Ligand Pharmaceuticals - LGND Stock Forecast, Price & News

$96.34
+1.70 (+1.80%)
(As of 10/6/2022 09:50 AM ET)
Add
Compare
Today's Range
$94.91
$96.34
50-Day Range
$77.13
$107.56
52-Week Range
$72.57
$169.98
Volume
459 shs
Average Volume
158,165 shs
Market Capitalization
$1.63 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$177.00

Ligand Pharmaceuticals MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
83.7% Upside
$177.00 Price Target
Short Interest
Bearish
5.21% of Float Sold Short
Dividend Strength
N/A
Sustainability
-2.19
Upright™ Environmental Score
News Sentiment
0.31mentions of Ligand Pharmaceuticals in the last 14 days
Based on 3 Articles This Week
Insider Trading
Selling Shares
$180,000 Sold Last Quarter
Proj. Earnings Growth
38.33%
From $1.20 to $1.66 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.51 out of 5 stars

Medical Sector

207th out of 1,072 stocks

Pharmaceutical Preparations Industry

87th out of 534 stocks

LGND stock logo

About Ligand Pharmaceuticals (NASDAQ:LGND) Stock

Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, focuses on developing or acquiring technologies that help pharmaceutical companies to discover and develop medicines worldwide. Its commercial programs include Kyprolis and Evomela, which are used to treat multiple myeloma; Veklury for the treatment of moderate or severe COVID-19; Teriparatide injection product for osteoporosis; Vaxneuvance for the prevention of invasive disease caused by Streptococcus pneumoniae; and Pneumosil, a pneumococcal conjugate vaccine to help fight against pneumococcal pneumonia among children. The company also offers Rylaze, a recombinant erwinia asparaginase for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma in adult and pediatric patients; and Nexterone, a captisol-enabled formulation of amiodarone; and Zulresso, a captisol-enabled formulation of brexanolone for the treatment of postpartum depression. In addition, it provides Noxafil-IV, a captisol-enabled formulation of posaconazole for IV use; Duavee for the treatment of postmenopausal osteoporosis; Aziyo portfolio of commercial pericardial repair and CanGaroo envelope extracellular matrix products; Exemptia for autoimmune diseases; Vivitra for breast cancer; Bryxta and Zybev for various indications; and Minnebro for the treatment of hypertension. The company's partners and licenses programs, which are in clinical development used for the treatment of cancer, seizure, diabetes, cardiovascular disease, muscle wasting, liver and kidney disease, and other diseases. Further, it sells Captisol materials. The company was incorporated in 1987 and is headquartered in Emeryville, California.

Receive LGND Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Ligand Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

LGND Stock News Headlines

Ligand Pharmaceuticals: Struggling Along
Ligand Pharmaceuticals Becomes Oversold (LGND)
Ligand Pharmaceuticals Becomes Oversold (LGND)
Ligand Pharmaceuticals Inc Stock Downgraded (LGND)
Ligand Reports Second Quarter 2022 Financial Results
See More Headlines
Receive LGND Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Ligand Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

LGND Company Calendar

Last Earnings
11/09/2021
Today
10/06/2022
Next Earnings (Estimated)
11/08/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
Biotechnology
Sector
Medical
Current Symbol
NASDAQ:LGND
CUSIP
53220K50
Employees
154
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$177.00
High Stock Price Forecast
$310.00
Low Stock Price Forecast
$130.00
Forecasted Upside/Downside
+83.7%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
5 Analysts

Profitability

Net Income
$57.14 million
Pretax Margin
-5.22%

Debt

Sales & Book Value

Annual Sales
$277.13 million
Cash Flow
$9.08 per share
Book Value
$49.14 per share

Miscellaneous

Free Float
15,127,000
Market Cap
$1.63 billion
Optionable
Optionable
Beta
1.08

Key Executives

  • Mr. John L. HigginsMr. John L. Higgins (Age 52)
    CEO & Exec. Director
    Comp: $1.23M
  • Mr. Matthew W. FoehrMr. Matthew W. Foehr (Age 49)
    Pres & COO
    Comp: $909k
  • Mr. Matthew E. Korenberg (Age 47)
    Exec. VP of Fin. & CFO
    Comp: $753.25k
  • Mr. Charles S. Berkman J.D. (Age 53)
    Sr. VP, Gen. Counsel & Sec.
    Comp: $665.83k
  • Simon Latimer
    Head of Investor Relations
  • Mr. Todd Pettingill
    Director of Corp. Devel.
  • Ms. Audrey Warfield-Graham
    Sr. VP of HR
  • Dr. Keith Marschke
    Sr. VP of Biology & Scientific Affairs
  • Dr. Vincent D. Antle (Age 53)
    Sr. VP of Technical Operations & QA - Capitsol
  • Mr. Patrick Lucy
    Sr. VP & CBO Protein Expression Bus.













LGND Stock - Frequently Asked Questions

Should I buy or sell Ligand Pharmaceuticals stock right now?

5 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Ligand Pharmaceuticals in the last twelve months. There are currently 5 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" LGND shares.
View LGND analyst ratings
or view top-rated stocks.

What is Ligand Pharmaceuticals' stock price forecast for 2022?

5 Wall Street analysts have issued 1-year target prices for Ligand Pharmaceuticals' stock. Their LGND share price forecasts range from $130.00 to $310.00. On average, they predict the company's stock price to reach $177.00 in the next year. This suggests a possible upside of 87.0% from the stock's current price.
View analysts price targets for LGND
or view top-rated stocks among Wall Street analysts.

How have LGND shares performed in 2022?

Ligand Pharmaceuticals' stock was trading at $154.46 at the beginning of 2022. Since then, LGND shares have decreased by 38.7% and is now trading at $94.64.
View the best growth stocks for 2022 here
.

When is Ligand Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, November 8th 2022.
View our LGND earnings forecast
.

How were Ligand Pharmaceuticals' earnings last quarter?

Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) posted its quarterly earnings data on Tuesday, November, 9th. The biotechnology company reported $1.58 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.61 by $0.97. The biotechnology company had revenue of $64.84 million for the quarter, compared to analyst estimates of $60.46 million. Ligand Pharmaceuticals had a negative net margin of 3.13% and a positive trailing twelve-month return on equity of 5.49%. During the same period in the previous year, the firm earned $0.71 EPS.

What guidance has Ligand Pharmaceuticals issued on next quarter's earnings?

Ligand Pharmaceuticals updated its FY 2022 earnings guidance on Tuesday, September, 6th. The company provided earnings per share (EPS) guidance of $2.40-$3.00 for the period, compared to the consensus earnings per share estimate of $2.30. The company issued revenue guidance of $169.00 million-$188.00 million, compared to the consensus revenue estimate of $162.86 million.

What is John L. Higgins' approval rating as Ligand Pharmaceuticals' CEO?

1 employees have rated Ligand Pharmaceuticals Chief Executive Officer John L. Higgins on Glassdoor.com. John L. Higgins has an approval rating of 100% among the company's employees. This puts John L. Higgins in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Ligand Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Ligand Pharmaceuticals investors own include Jazz Pharmaceuticals (JAZZ), Micron Technology (MU), NVIDIA (NVDA), Alibaba Group (BABA), Intel (INTC), AbbVie (ABBV), Netflix (NFLX), Cisco Systems (CSCO), Illumina (ILMN) and Gilead Sciences (GILD).

What is Ligand Pharmaceuticals' stock symbol?

Ligand Pharmaceuticals trades on the NASDAQ under the ticker symbol "LGND."

How do I buy shares of Ligand Pharmaceuticals?

Shares of LGND stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Ligand Pharmaceuticals' stock price today?

One share of LGND stock can currently be purchased for approximately $94.64.

How much money does Ligand Pharmaceuticals make?

Ligand Pharmaceuticals (NASDAQ:LGND) has a market capitalization of $1.60 billion and generates $277.13 million in revenue each year. The biotechnology company earns $57.14 million in net income (profit) each year or ($0.46) on an earnings per share basis.

How many employees does Ligand Pharmaceuticals have?

The company employs 154 workers across the globe.

How can I contact Ligand Pharmaceuticals?

Ligand Pharmaceuticals' mailing address is 3911 SORRENTO VALLEY BLVD SUITE 110, SAN DIEGO CA, 92121. The official website for the company is www.ligand.com. The biotechnology company can be reached via phone at (858) 550-7500, via email at investors@ligand.com, or via fax at 858-550-1826.

This page (NASDAQ:LGND) was last updated on 10/6/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access members have access to premium reports, best-in-class portfolio monitoring tools, and our latest stock picks.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies, and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.